Sidgiddi, S., Ranganathan, U. and Gautam, A. 2017. DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s46. DOI:https://doi.org/10.25251/skin.1.supp.45.